Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Superbug hijacks the wound healing system to cause serious and persistent disease

Monash University researchers have discovered that the devastating bacterial superbug Clostridioides difficile hijacks the human wound healing system in order to cause serious and persistent disease, opening up the development of new therapies to treat the disease.

25 Jun 2020

Novel sensor may be able to test for COVID-19 and influenza simultaneously

The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.

25 Jun 2020

Zika virus during pregnancy can hamper vital collagen development in babies’ brains

Zika virus can hamper vital collagen development in the brains of babies whose mothers were infected with the disease while pregnant, new research reveals, as the search for a vaccine continues.

25 Jun 2020

Early childhood vaccinations may offer protection against COVID-19

A group of Lithuanian and Kurdish scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19.

25 Jun 2020

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

The current COVID-19 pandemic is still very much active in most parts of the world. In the absence of effective antiviral drugs or vaccines, scientists are studying the use of blood plasma from convalescent COVID-19 patients, banking on its neutralizing antibody content.

25 Jun 2020

Protein profile in serum reflects COVID-19 severity

The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.

25 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

Structured 'cut-and-paste' design enables streamlined development of SARS-CoV-2 molecular probes

A seminal study by US researchers, currently available on the bioRxiv* preprint server, demonstrates how structure-based design can be efficiently employed to develop molecular probes targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and its domains, with possible future use in diagnostics, treatment and vaccine development.

24 Jun 2020

Kerafast offers the Delta-G-VSV Pseudotyping System for coronavirus research

Kerafast Inc., developers of an online platform to facilitate access to unique lab-made bioresearch materials, today announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by the Michael Whitt laboratory at University of Tennessee, enables studies of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment.

From Kerafast 24 Jun 2020

USA riddled with SARS-CoV-2 - 80% undetected

The coronavirus pandemic is actively spreading across the globe, affecting 188 countries and territories. The United States remains the country with the highest number of infections. The official tally reveals that the U.S. has more than 2.347 million people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Jun 2020

New study defines the transmission of COVID-19 from mother to child

UC Davis Health researchers took a critical step in defining the possible paths for the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causing COVID-19 to get transmitted from the mother to her newborn baby. The mother to fetal transmission is known as "vertical" transmission.

24 Jun 2020

Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion

A new study by researchers at Strasbourg University Hospital and published on the preprint server medRxiv* in June 2020 shows that COVID-19 antibody responses may sometimes be lacking following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could lead to a significant underestimation of the number of infections and the number of individuals who have achieved immunity.

24 Jun 2020

Experts identify steps to expand, improve serology tests for COVID-19

More than 300 scientists and clinicians from the federal government, industry and academia published a report of their conclusions and recommendations on COVID-19 serology studies online in Immunity.

23 Jun 2020

Male COVID-19 patients produce more SARS-CoV-2 antibodies than women

Health officials in the United Kingdom urge male coronavirus survivors to donate blood, particularly its convalescent plasma component. This comes after a new study has found that men produce more antibodies, which could make their plasma a valuable treatment against the coronavirus disease (COVID-19).

23 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

Research shows females use anti-inflammatory T cells to maintain their blood pressure

In the face of a multipronged front to drive blood pressure up, including a high-salt diet, females are better able to keep their pressure down by increasing levels of a T cell that selectively dials back inflammation, scientists say.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020